

CLAIMS

1. Association comprising 1) an antioxidant agent and 2) a mixed PPAR ligand for the α and γ receptor sub-types, or a selective PPAR ligand for the α receptor sub-type and a selective PPAR ligand for the γ receptor sub-type.
- 5 2. Association according to claim 1, wherein the PPAR ligand is a mixed ligand for the α and γ receptor sub-types.
3. Association according to claim 1, comprising a selective ligand for the α receptor sub-type and a selective ligand for the γ receptor sub-type.
- 10 4. Association according to claim 1, wherein the selective PPAR ligand for the γ receptor sub-type is rosiglitazone or an addition salt thereof with a pharmaceutically acceptable acid or base.
5. Association according to claim 1, wherein the antioxidant agent is ubiquinone or coenzyme Q₁₀.
6. Association, which is rosiglitazone and coenzyme Q₁₀.
- 15 7. Pharmaceutical compositions comprising as active ingredient one or more PPAR ligands in association with an antioxidant agent according to one of claims 1 to 6, on their own or in combination with one or more pharmaceutically acceptable excipients.
8. Pharmaceutical compositions according to claim 7 for use in the manufacture of a medicament for the treatment and/or prevention of obesity.
- 20 9. Pharmaceutical compositions according to claim 7 for use in the manufacture of a medicament for the treatment of obesity caused by a therapeutic treatment.

10. Pharmaceutical compositions according to claim 7 for use in the manufacture of a medicament for the treatment of obesity caused by treatment for type I or II diabetes.

11. Pharmaceutical compositions according to claim 7 for use in the manufacture of a medicament for the treatment and/or prevention of overweight characterised by a body mass index greater than 25 and less than 30.

12. Pharmaceutical compositions according to claim 7 for use in the manufacture of a medicament for the treatment of overweight characterised by a body mass index greater than 25 and less than 30 caused by a therapeutic treatment.

13. Pharmaceutical compositions according to claim 7 for use in the manufacture of a medicament for the treatment of overweight characterised by a body mass index greater than 25 and less than 30 caused by treatment for type I or II diabetes.

14. Use of an association comprising one or more PPAR ligands and an antioxidant agent in obtaining pharmaceutical compositions intended for the treatment and/or prevention of obesity.

15. Use of an association according to one of claims 1 to 6 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of obesity.

16. Use of an association comprising one or more PPAR ligands and an antioxidant agent in obtaining pharmaceutical compositions intended for the treatment and/or prevention of obesity caused by a therapeutic treatment.

17. Use of an association according to one of claims 1 to 6 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of obesity caused by a therapeutic treatment.

18. Use of an association comprising one or more PPAR ligands and an antioxidant agent in obtaining pharmaceutical compositions intended for the treatment and/or prevention of obesity caused by treatment for type I or II diabetes.

5 **19.** Use of an association according to one of claims 1 to 6 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of obesity caused by treatment for type I or II diabetes.

20. Use of an association comprising one or more PPAR ligands and an antioxidant agent in obtaining pharmaceutical compositions intended for the treatment and/or prevention of overweight characterised by a body mass index greater than 25 and less than 30.

10 **21.** Use of an association according to one of claims 1 to 6 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of overweight characterised by a body mass index greater than 25 and less than 30.

22. Use of an association comprising one or more PPAR ligands and an antioxidant agent in obtaining pharmaceutical compositions intended for the treatment and/or prevention of
15 overweight characterised by a body mass index greater than 25 and less than 30 caused by a therapeutic treatment.

23. Use of an association according to one of claims 1 to 6 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of overweight characterised by a body mass index greater than 25 and less than 30 caused by a therapeutic treatment.

20 **24.** Use of an association comprising one or more PPAR ligands and an antioxidant agent in obtaining pharmaceutical compositions intended for the treatment and/or prevention of overweight characterised by a body mass index greater than 25 and less than 30 caused by treatment for type I or II diabetes.

25. Use of an association according to one of claims 1 to 6 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of overweight characterised by a

body mass index greater than 25 and less than 30 caused by treatment for type I or II diabetes.